The Ultrasound Elastography System segmentation by application delineates six primary clinical domains: Liver, Breast, Thyroid, Prostate, Musculoskeletal and Other. The liver segment dominates the market, accounting for roughly 35 % of total revenue, driven by the high prevalence of chronic liver disease and the technology’s ability to quantify fibrosis non‑invasively. Breast elastography follows with an estimated 25 % share, reflecting its integration into routine oncology screening and the demand for precise lesion characterization. Thyroid applications contribute about 15 % as elastography aids in distinguishing benign from malignant nodules, influencing surgical decision‑making. Prostate elastography, at 10 %, is propelled by rising prostate‑cancer screening initiatives and the need for targeted biopsy guidance. The musculoskeletal sector also represents 10 % of the market, supporting assessments of tendon pathology and muscle stiffness in sports medicine. The residual 5 % classified as “Other” includes emerging uses such as pancreatic, renal and vascular elastography, which together add incremental growth but remain a minor share of overall market size.